September 9, 2026 Starton Therapeutics to Present at the 17th Annual World Bispecific Summit in Boston
September 8, 2026 Starton Therapeutics Appoints Experienced Finance Executive Saleem Elmasri, CPA, as Chief Financial Officer
August 13, 2026 The Galien Foundation Announces 2026 Prix Galien USA Nominees for “Best Digital Health Solution,” “Best Medical Technology,” “Incubators, Accelerators and Equity,” and “Best Startup”
March 5, 2026 Starton Therapeutics Files Patent Applications for the Use of CAR-T Therapies in Combination with its Proprietary, Continuous Low-Dose Immunomodulatory Therapy, STAR-LLD, a formulation of Lenalidomide, for the Treatment of Blood Cancer
February 26, 2026 Starton Therapeutics Files Patent Application for the Use of Multi-Specific Antibody-Based Therapies in Combination with its Proprietary, Continuous Low-Dose Immunomodulatory Therapy, STAR-LLD, a formulation of Lenalidomide, for the Treatment of Blood Cancer
February 19, 2026 Starton Therapeutics Announces Dosing of First Patient in Phase 2a Study Evaluating STAR-LLD for the Treatment of Multiple Myeloma
October 8, 2025 Starton Therapeutics to Share Innovative Lenalidomide Delivery Technology on Labroots Webinar Sponsored by Primetech Corporation
October 2, 2025 Starton Therapeutics Announces Promotion of Rod Hartwig to Vice President of Research and Development and Manufacturing
October 1, 2025 Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025
September 16, 2025 Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD
